Seborrhea - Pipeline Review, H2 2020
Seborrhea - Pipeline Review, H2 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H2 2020, provides an overview of the Seborrhea (Dermatology) pipeline landscape.
Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Seborrhea - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Discovery and Unknown stages are 1, 2, 1 and 2 respectively.
Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H2 2020, provides an overview of the Seborrhea (Dermatology) pipeline landscape.
Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Seborrhea - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Discovery and Unknown stages are 1, 2, 1 and 2 respectively.
Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Seborrhea - Overview
Seborrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Seborrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Seborrhea - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arcutis Inc
Cutanea Life Sciences Inc
DermBiont Inc
Vyome Therapeutics Inc
Seborrhea - Drug Profiles
ARQ-154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Seborrhea - Dormant Projects
Seborrhea - Discontinued Products
Seborrhea - Product Development Milestones
Featured News & Press Releases
Jun 22, 2020: Arcutis enrolls last patient in phase 2 proof of concept clinical trial evaluating ARQ-154 (Topical Roflumilast Foam) as a potential treatment for Seborrheic Dermatitis
Dec 05, 2019: Arcutis announces ARQ-154 program for seborrheic dermatitis and enrollment of first patient in phase 2 proof of concept clinical trial
Feb 28, 2019: Aclaris Therapeutics Receives European Approvals of ESKATA (hydrogen peroxide) cutaneous solution, 685 mg
Dec 18, 2018: Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
Oct 01, 2018: Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA (hydrogen peroxide) Topical Solution 40%, (w/w)
Jun 12, 2018: Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris ESKATA is safe and effective in treating persons with raised seborrheic keratoses
May 30, 2018: Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA
May 16, 2018: Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
May 07, 2018: Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)
Feb 08, 2018: Aclaris Therapeutics to Present Data on ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
Dec 15, 2017: Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
Sep 19, 2017: Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aug 03, 2017: Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
Jun 13, 2017: Aclaris Therapeutics Announces Issuance of New US Patent For A-101 Topical Solutions
May 09, 2017: FDA Accepts Aclaris Therapeutics' New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Seborrhea - Overview
Seborrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Seborrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Seborrhea - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Arcutis Inc
Cutanea Life Sciences Inc
DermBiont Inc
Vyome Therapeutics Inc
Seborrhea - Drug Profiles
ARQ-154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Seborrhea - Dormant Projects
Seborrhea - Discontinued Products
Seborrhea - Product Development Milestones
Featured News & Press Releases
Jun 22, 2020: Arcutis enrolls last patient in phase 2 proof of concept clinical trial evaluating ARQ-154 (Topical Roflumilast Foam) as a potential treatment for Seborrheic Dermatitis
Dec 05, 2019: Arcutis announces ARQ-154 program for seborrheic dermatitis and enrollment of first patient in phase 2 proof of concept clinical trial
Feb 28, 2019: Aclaris Therapeutics Receives European Approvals of ESKATA (hydrogen peroxide) cutaneous solution, 685 mg
Dec 18, 2018: Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
Oct 01, 2018: Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA (hydrogen peroxide) Topical Solution 40%, (w/w)
Jun 12, 2018: Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris ESKATA is safe and effective in treating persons with raised seborrheic keratoses
May 30, 2018: Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA
May 16, 2018: Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
May 07, 2018: Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)
Feb 08, 2018: Aclaris Therapeutics to Present Data on ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
Dec 15, 2017: Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
Sep 19, 2017: Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
Aug 03, 2017: Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
Jun 13, 2017: Aclaris Therapeutics Announces Issuance of New US Patent For A-101 Topical Solutions
May 09, 2017: FDA Accepts Aclaris Therapeutics' New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Seborrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2020
Seborrhea - Pipeline by Arcutis Inc, H2 2020
Seborrhea - Pipeline by Cutanea Life Sciences Inc, H2 2020
Seborrhea - Pipeline by DermBiont Inc, H2 2020
Seborrhea - Pipeline by Vyome Therapeutics Inc, H2 2020
Seborrhea - Dormant Projects, H2 2020
Seborrhea - Discontinued Products, H2 2020
Number of Products under Development for Seborrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2020
Seborrhea - Pipeline by Arcutis Inc, H2 2020
Seborrhea - Pipeline by Cutanea Life Sciences Inc, H2 2020
Seborrhea - Pipeline by DermBiont Inc, H2 2020
Seborrhea - Pipeline by Vyome Therapeutics Inc, H2 2020
Seborrhea - Dormant Projects, H2 2020
Seborrhea - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Seborrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Arcutis Inc
Cutanea Life Sciences Inc
DermBiont Inc
Vyome Therapeutics Inc
Number of Products under Development for Seborrhea, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Arcutis Inc
Cutanea Life Sciences Inc
DermBiont Inc
Vyome Therapeutics Inc
